2-[1-Methyl-5-(4-methylphenyl)pyrrol-2-yl]acetic acid | 617721-52-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 2-[1-Methyl-5-(4-methylphenyl)pyrrol-2-yl]acetic acid
• CAS: 617721-52-5
• 化学式: C₁₄H₁₅NO₂
• 分子量: 229.279
• InChiKey: ZZBQRGHQSPLVIS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  42.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-[1-Methyl-5-(4-methylphenyl)pyrrol-2-yl]acetic acid 、 8-[(3-N-methylamino-2,6-dimethylbenzyl)oxy]-2-methyl quinoline 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 盐酸 作用下， 以 二氯甲烷 、 乙醚 为溶剂， 反应 16.0h， 生成 N-[2,4-dimethyl-3-(2-methyl-quinolin-8-yloxymethyl)-phenyl]-N-methyl-2-(1-methyl-5-p-tolyl-1H-pyrrol-2-yl)-acetamide hydrochloride
  参考文献：
  名称：

  [EN] NOVEL HETEROARYL ALKYLAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR MODULATORS
  [FR] NOUVEAUX DERIVES HETEROARYLALKYLAMIDE UTILES EN TANT QUE MODULATEURS DU RECEPTEUR DE LA BRADYKININE

  摘要：

  公开号：

  WO2003087090A3
• 作为产物：
  描述：

  2-[1-Methyl-5-(4-methylphenyl)pyrrol-2-yl]acetonitrile 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 3.0h， 生成 2-[1-Methyl-5-(4-methylphenyl)pyrrol-2-yl]acetic acid
  参考文献：
  名称：

  Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators

  摘要：

  这项发明涉及新颖的烷基酰胺衍生物，作为布雷金肽受体拮抗剂，用于治疗布雷金肽调节的疾病，如疼痛、炎症、哮喘和过敏。此外，该发明涉及新颖的烷基酰胺衍生物，作为布雷金肽受体激动剂，用于治疗布雷金肽调节的疾病，如高血压等。

  公开号：

  US20040192720A1

文献信息

• 1-Methyl-5-p-methylbenzoylpyrrole-2-acetamidoacetanilides with anti-inflammatory, analgesic, antipyretic and antiplatelet aggregant activity
  申请人：Medosan Industrie Biochimiche Riunite S.p.A.

  公开号：EP0134763A1

  公开（公告）日：1985-03-20

  The anilide derivates of 1-methyl-5-p-methylbenzoyl- pyrrole-2-acetamidoacetic acid are described, with general formula in which R, R', R" and R" may be hydrogen, halogen, alkyl, alkoxyl or a trifluoromethyl group.

  描述了 1-甲基-5-对甲基苯甲酰基吡咯-2-乙酰胺基乙酸的苯胺衍生物，通式为 其中 R、R'、R "和 R "可以是氢、卤素、烷基、烷氧基或三氟甲基。
• Dosage form with means for governing rate of gas formation
  申请人：ALZA CORPORATION

  公开号：EP0250083A2

  公开（公告）日：1987-12-23

  A dosage form (20) for delivering a beneficial drug formulation (26) to an environment of use, comprising: a) a wall (22) comprising at least in part a composition permeable to the passage of fluid and substantially impermeable to the passage of a drug formulation (26) which wall surrounds and defines; b) a compartment (25); c) a dosage amount of a beneficial drug formulation in the compartment; and d) exit means (23) in the wall of the dosage form that connects compartment (25) with the exterior of the dosage form for delivering the drug formulation (26) from the dosage form; characterised by e) means for producing a biologically acceptable gas (27) in the compartment, said means comprising a pharmaceutically acceptable gas release rate controlling means (28); characterised by c) a dosage amount of an anti-inflammatory drug selected from an acylcarboxylic acid or enolic acid anti-inflammatory drug in the compartment (25); and by d) means (27) for producing gaseous carbon dioxide in the compartment, said means comprising a polymeric film (28) surrounding a member selected from a carbonate and bicarbonate.

  一种将有益药物制剂（26）输送到使用环境中的剂型（20），包括 a) 壁（22），该壁至少部分由可渗透流体并基本不透过药物制剂（26）的成分组成，该壁包围并限定了药物制剂（26）； b) 隔室（25） c) 小室中有益药物制剂的剂量；以及 d) 位于剂型壁上的出口装置（23），用于连接隔室（25）和剂型外部，以便将药物制剂 （26）从剂型中输送出来； 其特征是 e) 在隔室中产生生物可接受气体（27）的装置，所述装置包括药物可接受气体释放速率控制装置（28）； 其特征是 d) 在隔室中产生气态二氧化碳的装置（27），所述装置包括围绕选自碳酸盐和碳酸氢盐的构件的聚合物薄膜（28）。
• Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein
  申请人：Board of Regents, The University of Texas System

  公开号：EP2065047A1

  公开（公告）日：2009-06-03

  Disclosed are compositions comprising non-steroid anti-inflammatory drugs (NSAID's) complexed with zwitterionic, neutral phospholipids, or both, having reduced gastrointestinal irritating effects and enhanced anti-pyretic, analgesic, and anti-inflammatory activity. Also disclosed are improved methods of using the complexes for treating fever, inflammation, and preventing platelet aggregation. In some embodiments, the anti-pyretic activity of sub-therapeutically used amounts of NSAID's are enhanced to elicit anti-pyretic activity in vivo when associated (noncovalently) with zwitterionic phospholipids, such as dipalmitoyl phosphatidyl choline.

  本发明公开了由非甾体抗炎药（NSAID）与滋养型磷脂、中性磷脂或两者复合物组成的复合物，其胃肠道刺激作用减弱，抗发热、镇痛和抗炎活性增强。还公开了使用复合物治疗发热、炎症和防止血小板聚集的改进方法。在某些实施方案中，当非甾类抗炎药与齐聚物磷脂（如二棕榈酰磷脂酰胆碱）（非共价）结合时，亚治疗用量的非甾类抗炎药的抗热退烧活性增强，从而在体内激发抗热退烧活性。
• METHODS OF ENHANCING THE THERAPEUTIC ACTIVITY OF NSAIDS AND COMPOSITIONS OF ZWITTERIONIC PHOSPHOLIPIDS USEFUL THEREIN
  申请人：BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM

  公开号：EP0805684B1

  公开（公告）日：2002-06-12
• Methods of enhancing the therapeutic activity of NSAIDs and compositions of zwitterionic phospholipids useful therein
  申请人：Board of Regents, The University of Texas System

  公开号：EP1214940B1

  公开（公告）日：2009-03-11